TA
MCID: TKY002
MIFTS: 61

Takayasu Arteritis (TA)

Categories: Blood diseases, Bone diseases, Cardiovascular diseases, Fetal diseases, Nephrological diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Takayasu Arteritis

MalaCards integrated aliases for Takayasu Arteritis:

Name: Takayasu Arteritis 56 12 74 52 58 43 17 71
Aortic Arch Syndrome 56 12 52
Young Female Arteritis 56 52
Aortic Arch Syndromes 43 71
Takayasu's Arteritis 12 15
Aortic Arches Defect 74 52
Idiopathic Aortitis 12 71
Aortic Arch Defects 52 58
Pulseless Disease 56 52
Aortic Arch Arteritis 12
Takayasu's Disease 12
Takayasu Disease 52
Ta 52

Characteristics:

Orphanet epidemiological data:

58
takayasu arteritis
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),<1/1000000 (United Kingdom),1-9/100000 (Japan),1-9/1000000 (Sweden),1-9/1000000 (United Kingdom); Age of onset: Adolescent,Adult; Age of death: adult;
aortic arch defects
Inheritance: Not applicable; Age of onset: Childhood;

OMIM:

56
Inheritance:
? autosomal recessive vs. autoimmune


HPO:

31
takayasu arteritis:
Inheritance autosomal recessive inheritance


Classifications:

Orphanet: 58  
Rare circulatory system diseases
Rare cardiac malformations
Rare renal diseases
Rare respiratory diseases
Rare systemic and rhumatological diseases
Developmental anomalies during embryogenesis


Summaries for Takayasu Arteritis

NIH Rare Diseases : 52 Takayasu arteritis is a condition that causes inflammation of the main blood vessel that carries blood from the heart to the rest of the body (aorta ) and its associated branched blood vessels. As a result of the inflammation, the blood vessel walls become thick and make it difficult for blood to flow. Over time, impaired blood flow causes damage to the heart and various other organs of the body. Although the cause remains unknown, Takayasu arteritis appears to be an autoimmune condition, in which cells that fight infection and disease are wrongly targeted against the body's own tissues .

MalaCards based summary : Takayasu Arteritis, also known as aortic arch syndrome, is related to vasculitis and aortic aneurysm. An important gene associated with Takayasu Arteritis is HLA-B (Major Histocompatibility Complex, Class I, B), and among its related pathways/superpathways are Innate Immune System and Class I MHC mediated antigen processing and presentation. The drugs Omega 3 Fatty Acid and Azathioprine have been mentioned in the context of this disorder. Affiliated tissues include heart, bone and kidney, and related phenotypes are hyperhidrosis and fatigue

Disease Ontology : 12 A syndrome that involves inflammation of the aorta that carries blood from the heart to the rest of the body.

Wikipedia : 74 Interrupted aortic arch is a very rare heart defect (affecting 3 per million live births) in which the... more...

More information from OMIM: 207600

Related Diseases for Takayasu Arteritis

Diseases related to Takayasu Arteritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 847)
# Related Disease Score Top Affiliating Genes
1 vasculitis 32.6 VCAM1 TNF THBD SELE PTX3 IL6
2 aortic aneurysm 31.7 MMP9 MMP3 IL6 CRP
3 aortitis 31.7 TNF IL6 CRP CD40LG
4 ulcerative colitis 31.6 TNF IL6 ICAM1 HLA-DRB1 CRP
5 coronary stenosis 31.6 IL6 ICAM1 CRP
6 pyoderma 31.5 TNF MMP9 CRP
7 crohn's disease 31.4 TNF IL6 HLA-DRB1 CRP
8 aortic aneurysm, familial abdominal, 1 31.4 MMP9 MMP3 IL6 CRP
9 intermediate coronary syndrome 31.3 VCAM1 IL6 ICAM1 CRP
10 intermittent claudication 31.3 IL6 CRP CD40LG
11 optic nerve disease 31.2 TNF IL6 CRP CD40LG
12 cardiogenic shock 31.2 IL6 CRP
13 temporal arteritis 31.2 TNF IL6 HLA-DRB1 CRP CD40LG
14 pericarditis 31.2 TNF IL6 CRP CD40LG
15 spondylitis 31.1 TNF MICA IL6 HLA-B CRP
16 pulmonary tuberculosis 31.1 TNF IL6 IL12B HLA-DRB1 CRP
17 uveitis 31.1 TNF IL6 ICAM1 HLA-B HLA-A
18 subacute thyroiditis 31.1 TNF IL6 CRP
19 scleritis 31.1 TNF SELE MMP9 CRP
20 limb ischemia 31.1 TNF SELE MMP9 IL6 ICAM1
21 neuritis 31.1 VCAM1 TNF MMP9 IL6
22 optic neuritis 31.0 VCAM1 TNF HLA-DRB1
23 pericardial effusion 31.0 IL6 CRP CD40LG
24 exanthem 31.0 TNF IL6 CRP CD40LG
25 coronary aneurysm 31.0 TNF MMP9 MMP3 CRP
26 collagen disease 31.0 TNF IL6 CRP CD40LG
27 spondyloarthropathy 1 31.0 TNF MMP3 HLA-B CRP CD40LG
28 familial mediterranean fever 31.0 TNF IL6 HLA-A CRP
29 infective endocarditis 31.0 TNF IL6 FCGR2A CRP
30 sarcoidosis 1 30.9 TNF ICAM1 HLA-DRB1 HLA-A CRP CD40LG
31 carotid stenosis 30.9 VCAM1 TNF SELE MMP9 ICAM1 CRP
32 endocarditis 30.9 VCAM1 TNF IL6 FCGR2A CRP
33 acute myocardial infarction 30.9 THBD SELE PTX3 MMP9 IL6 CRP
34 purpura 30.9 TNF THBD IL6 CRP CD40LG
35 myocarditis 30.9 VCAM1 TNF IL6 ICAM1 HLA-B CD40LG
36 polyarteritis nodosa 30.9 VCAM1 SELE IL6 ICAM1 HLA-DRB1 CRP
37 lymphadenitis 30.9 TNF PTX3 ICAM1 CRP
38 microscopic polyangiitis 30.9 TNF HLA-DRB1 FCGR2A
39 antiphospholipid syndrome 30.9 VCAM1 TNF THBD SELE CRP CD40LG
40 chronic recurrent multifocal osteomyelitis 30.9 TNF IL6 CRP
41 respiratory failure 30.9 TNF THBD PTX3 IL6 CRP
42 end stage renal failure 30.8 TNF THBD IL6 CRP
43 retinal vein occlusion 30.8 TNF PTX3 IL6 CD40LG
44 microscopic colitis 30.8 TNF IL6 HLA-DRB1
45 spinal cord injury 30.8 TNF MMP9 IL6
46 posterior scleritis 30.8 TNF CRP
47 granulomatosis with polyangiitis 30.8 TNF SELE HLA-DPB1 CRP CD40LG
48 placenta disease 30.8 TNF IL6 CRP
49 abdominal tuberculosis 30.8 TNF CRP CD40LG
50 polyclonal hypergammaglobulinemia 30.7 IL6 CRP CD40LG

Graphical network of the top 20 diseases related to Takayasu Arteritis:



Diseases related to Takayasu Arteritis

Symptoms & Phenotypes for Takayasu Arteritis

Human phenotypes related to Takayasu Arteritis:

58 31 (show all 49)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hyperhidrosis 58 31 hallmark (90%) Very frequent (99-80%) HP:0000975
2 fatigue 58 31 hallmark (90%) Very frequent (99-80%) HP:0012378
3 fever 58 31 hallmark (90%) Very frequent (99-80%) HP:0001945
4 subcutaneous nodule 58 31 hallmark (90%) Very frequent (99-80%) HP:0001482
5 weight loss 58 31 hallmark (90%) Very frequent (99-80%) HP:0001824
6 hypertensive crisis 58 31 hallmark (90%) Very frequent (99-80%) HP:0100735
7 vasculitis 58 31 hallmark (90%) Very frequent (99-80%) HP:0002633
8 abnormal aortic arch morphology 31 hallmark (90%) HP:0012303
9 seizures 58 31 frequent (33%) Frequent (79-30%) HP:0001250
10 muscle weakness 58 31 frequent (33%) Frequent (79-30%) HP:0001324
11 respiratory insufficiency 58 31 frequent (33%) Frequent (79-30%) HP:0002093
12 arthritis 58 31 frequent (33%) Frequent (79-30%) HP:0001369
13 hypertrophic cardiomyopathy 58 31 frequent (33%) Frequent (79-30%) HP:0001639
14 anemia 58 31 frequent (33%) Frequent (79-30%) HP:0001903
15 myocardial infarction 58 31 frequent (33%) Frequent (79-30%) HP:0001658
16 pulmonary arterial hypertension 58 31 frequent (33%) Frequent (79-30%) HP:0002092
17 skin ulcer 58 31 frequent (33%) Frequent (79-30%) HP:0200042
18 abnormal pattern of respiration 58 31 frequent (33%) Frequent (79-30%) HP:0002793
19 myalgia 58 31 frequent (33%) Frequent (79-30%) HP:0003326
20 chest pain 58 31 frequent (33%) Frequent (79-30%) HP:0100749
21 gangrene 58 31 frequent (33%) Frequent (79-30%) HP:0100758
22 anorexia 58 31 frequent (33%) Frequent (79-30%) HP:0002039
23 migraine 58 31 frequent (33%) Frequent (79-30%) HP:0002076
24 apnea 58 31 frequent (33%) Frequent (79-30%) HP:0002104
25 inflammatory abnormality of the eye 58 31 frequent (33%) Frequent (79-30%) HP:0100533
26 ascending tubular aorta aneurysm 31 frequent (33%) HP:0004970
27 abnormal aortic valve morphology 31 frequent (33%) HP:0001646
28 neurological speech impairment 58 31 occasional (7.5%) Occasional (29-5%) HP:0002167
29 recurrent respiratory infections 58 31 occasional (7.5%) Occasional (29-5%) HP:0002205
30 reduced consciousness/confusion 58 31 occasional (7.5%) Occasional (29-5%) HP:0004372
31 feeding difficulties in infancy 58 31 occasional (7.5%) Occasional (29-5%) HP:0008872
32 retinopathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0000488
33 arthralgia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002829
34 cerebral ischemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002637
35 amaurosis fugax 58 31 occasional (7.5%) Occasional (29-5%) HP:0100576
36 hemoptysis 58 31 occasional (7.5%) Occasional (29-5%) HP:0002105
37 asthma 58 31 occasional (7.5%) Occasional (29-5%) HP:0002099
38 gastrointestinal infarctions 58 31 occasional (7.5%) Occasional (29-5%) HP:0005244
39 abnormal endocardium morphology 31 occasional (7.5%) HP:0004306
40 hypertension 58 Frequent (79-30%)
41 abnormal heart valve morphology 58 Very frequent (99-80%)
42 abnormality of the aortic valve 58 Frequent (79-30%)
43 abnormality of the endocardium 58 Occasional (29-5%)
44 dilatation of the ascending aorta 58 Frequent (79-30%)
45 abnormality of the aortic arch 58 Very frequent (99-80%)
46 arterial stenosis 58 Very frequent (99-80%)
47 aneurysm 58 Very frequent (99-80%)
48 increased inflammatory response 58 Frequent (79-30%)
49 arteritis 31 HP:0012089

Symptoms via clinical synopsis from OMIM:

56
Vascular:
arteritis, major aortic branches

Limbs:
decreased pulses, upper limbs

Clinical features from OMIM:

207600

GenomeRNAi Phenotypes related to Takayasu Arteritis according to GeneCards Suite gene sharing:

26 (show all 16)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-103 9.74 HLA-A HLA-B
2 Increased shRNA abundance (Z-score > 2) GR00366-A-110 9.74 HLA-A HLA-B
3 Increased shRNA abundance (Z-score > 2) GR00366-A-118 9.74 HLA-A HLA-B
4 Increased shRNA abundance (Z-score > 2) GR00366-A-121 9.74 MICA
5 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.74 SELE
6 Increased shRNA abundance (Z-score > 2) GR00366-A-178 9.74 HLA-A HLA-B
7 Increased shRNA abundance (Z-score > 2) GR00366-A-189 9.74 SELE
8 Increased shRNA abundance (Z-score > 2) GR00366-A-19 9.74 HLA-A HLA-B MICA SELE
9 Increased shRNA abundance (Z-score > 2) GR00366-A-26 9.74 SELE
10 Increased shRNA abundance (Z-score > 2) GR00366-A-31 9.74 HLA-A HLA-B
11 Increased shRNA abundance (Z-score > 2) GR00366-A-39 9.74 SELE
12 Increased shRNA abundance (Z-score > 2) GR00366-A-46 9.74 MICA
13 Increased shRNA abundance (Z-score > 2) GR00366-A-57 9.74 MICA
14 Increased shRNA abundance (Z-score > 2) GR00366-A-7 9.74 HLA-A HLA-B
15 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.74 HLA-A HLA-B
16 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.74 MICA

MGI Mouse Phenotypes related to Takayasu Arteritis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.73 CD40LG FCGR2A ICAM1 IL12B IL6 MMP3
2 immune system MP:0005387 9.44 CD40LG CRP FCGR2A ICAM1 IL12B IL6

Drugs & Therapeutics for Takayasu Arteritis

Drugs for Takayasu Arteritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 68)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Omega 3 Fatty Acid Phase 4
2
Azathioprine Approved Phase 3 446-86-6 2265
3
Mycophenolic acid Approved Phase 3 24280-93-1 446541
4
Prednisone Approved, Vet_approved Phase 2, Phase 3 53-03-2 5865
5
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
6
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
7
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
8 Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
9
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
10
Upadacitinib Approved, Investigational Phase 3 1310726-60-3
11
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
12
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
13 Antitubercular Agents Phase 3
14 Anti-Infective Agents Phase 3
15 Antibiotics, Antitubercular Phase 3
16 Anti-Bacterial Agents Phase 3
17 Immunoglobulins Phase 3
18 Antibodies Phase 3
19 Gastrointestinal Agents Phase 3
20 Antirheumatic Agents Phase 2, Phase 3
21 Immunologic Factors Phase 2, Phase 3
22 Anti-Inflammatory Agents Phase 3
23 Hormone Antagonists Phase 3
24 Antineoplastic Agents, Hormonal Phase 3
25 glucocorticoids Phase 3
26 Hormones Phase 3
27 Immunosuppressive Agents Phase 2, Phase 3
28 Antiemetics Phase 3
29 Methylprednisolone Acetate Phase 3
30 Protective Agents Phase 3
31 Neuroprotective Agents Phase 3
32 Autonomic Agents Phase 3
33 Alkylating Agents Phase 2, Phase 3
34
Infliximab Approved Phase 2 170277-31-3
35
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
36
leucovorin Approved Phase 2 58-05-9 6006 143
37
Abatacept Approved Phase 2 332348-12-6 10237
38
Naltrexone Approved, Investigational, Vet_approved Phase 2 16590-41-3 5360515
39
Ethanol Approved Phase 2 64-17-5 702
40
Aldesleukin Approved Phase 2 110942-02-4, 85898-30-2
41
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
42 Dermatologic Agents Phase 2
43 Vitamin B Complex Phase 2
44 Folic Acid Antagonists Phase 2
45 Vitamin B9 Phase 2
46 Folate Phase 2
47 Antimetabolites Phase 2
48 Narcotics Phase 2
49 Narcotic Antagonists Phase 2
50 Interleukin-2 Phase 2

Interventional clinical trials:

(show all 50)
# Name Status NCT ID Phase Drugs
1 Protocol for a Randomized, Placebo-Controlled, Double-Blinded Trial to Study the Effects of Supplementary Omega-3 Fatty Acids on Serum C-Reactive Protein Levels Terminated NCT00578578 Phase 4
2 Comparison of the Efficacy of Mycophenolate Mofetil Combined With Methotrexate and Cyclophosphamide for the Treatment of Takayasu's Arteritis Unknown status NCT03096275 Phase 3 MMF;CYC;Glucocorticoids;MTX;AZA
3 Efficacy and Tolerance of First-line Treatment With Tocilizumab in Active Takayasu Arteritis French Prospective Multicenter Study Unknown status NCT02101333 Phase 3 Tocilizumab
4 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Upadacitinib in Subjects With Takayasu Arteritis (SELECT-Takayasu) Not yet recruiting NCT04161898 Phase 3 Upadacitinib;Placebo for Upadacitinib;Prednisolone
5 Does Inactive Takayasu Arteritis(NIH Criteria) Need Anti-inflammatory Treatment? Not yet recruiting NCT03550781 Phase 2, Phase 3 Prednisone, cyclophosphamide
6 Anti-tumor Necrosis Factor Therapy Effect on Takayasu Arteritis Unknown status NCT02457585 Phase 2 remicade (anti tumor necrosis factor inhibitor)
7 Concurrent Pilot Studies in Giant Cell Arteritis and Takayasu's Arteritis to Examine the Safety, Efficacy, and Immunologic Effects of Abatacept (CTLA4-Ig) in Large Vessel Vasculitis Completed NCT00556439 Phase 2 Abatacept;Placebo
8 An Open Trial of the Efficacy of Glucocorticoids and Methotrexate (MTX) in the Treatment of Systemic Vasculitis Completed NCT00001256 Phase 2 prednisone and methotrexate
9 Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis Recruiting NCT03482479 Phase 2 Naltrexone Hydrochloride
10 Induction of Regulatory t Cells by Low Dose IL2 in Autoimmune and Inflammatory Diseases: a Transnosographic Approach Recruiting NCT01988506 Phase 2 Interleukin 2
11 Effects of Exercise Training in Primary Sjogren´s Syndrome, Myositis and Takayasu's Arteritis Unknown status NCT01501019
12 A Prospective Observational Study of Infliximab Biosimilar in the Treatment of Takayasu's Arteritis Resistant to Corticosteroids and Conventional Immune-suppressive Treatments Unknown status NCT03192878 Infliximab
13 Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases Unknown status NCT00006055 anti-thymocyte globulin;cyclophosphamide;cyclosporine;filgrastim;methylprednisolone;prednisone
14 ACR/EULAR Endorsed Study to Develop New Diagnostic and Classification Criteria for Primary Systemic Vasculitis Unknown status NCT01066208
15 A Prospective Study of Using Parenchymal Blood Volume(PBV) for Endovascular Treatment of Renal Arterial Stenosis Unknown status NCT03252639
16 Pulmonary Artery Involvement in Takayasu's Arteritis: a Retrospective Study in China Completed NCT03189602
17 Contrast Enhanced Ultrasound for Assessment of Carotid Artery Neovascularization as a Marker of Disease Activity in Takayasu's Arteritis and Giant Cell Arteritis Completed NCT01795456
18 VCRC Imaging Protocol for Magnetic Resonance and Positron Emission Tomography in Large-vessel Vasculitis (Takayasu's Arteritis):Development as Clinical Trial Outcome Measures Completed NCT00744952
19 Reproductive Health in Men and Women With Vasculitis Completed NCT02176070
20 Impact and Utility of Positron Emission Tomography (PET) for the Assessment of Inflammatory Activity Arteritis Versus Clinical Score and Laboratory Values in Takayasu Arteritis: a Cohort Study Completed NCT01532167
21 VCRC Validation of Patient-Reported Diagnostic Data Completed NCT02190942
22 Educational Needs of Patients With Systemic Vasculitis- an International Survey Completed NCT02190929
23 Illness Perception, Fatigue, and Function in Systemic Vasculitis (The VCRC Vasculitis Perception (VIP) Study) Completed NCT02190916
24 The Long-term Success of Cardiovascular Surgery in Takayasu Arteritis. 30 Years of Experience in Mexico, Beyond Forefront Techniques Completed NCT03654222
25 The Biodistribution of 18F-Clofarabine in Patients With Autoimmune and Inflammatory Diseases Completed NCT02925351
26 The Journey of Patients With Vasculitis From First Symptom to Diagnosis Completed NCT03410290
27 Evaluation of Yellow Fever Vaccine in Patients With Rheumatic Diseases Under Low Immunosuppression Level and Residing in a Risk Area Completed NCT03430388
28 Impact of Vasculitis on Employment and Income. An Online Survey of Participants in the VCRC Patient Contact Registry Completed NCT02476292
29 A Head-to-Head Comparison of Color Doppler Ultrasonography (CDUS) and Magnetic Resonance Angiography (MRA) in Patients With Systemic Large Vessel Vasculitis (sLVV) - A Cross Sectional Study Completed NCT02042092
30 Comparison of the Efficacy and Safety of Leflunomide Versus Placebo Combine With the Basic Prednisone Therapy in Patients With Active Phase of Takayasu's Arteritis: a Randomized Controlled Double-blinded Trial Recruiting NCT02981979 Leflunomide 10mg Tab;Prednisone Acetate;Placebos
31 A Registry Study on Biomarkers of Takayasu's Arteritis Recruiting NCT03372980
32 Registration Study of Takayasu's Arteritis in China Recruiting NCT03199183
33 Exercise in Juvenile Takayasu Disease: a Randomized Controlled Trial Recruiting NCT03494062
34 Aerobic Capacity and Strength Exercise in Takayasu's Arteritis: Impact on Clinical, Laboratory and Vascular Parameters Recruiting NCT03750929
35 Takayasu Arteritis Activity Evaluation by Ultrafast Ultrasound Imaging Recruiting NCT03956394
36 VCRC Genetic Repository One-Time DNA Protocol Recruiting NCT01241305
37 The Cohort Study of East Chinese Takayasu's Arteritis (ECTA-cohort Study) Recruiting NCT03893136 Leflunomide
38 Observational Multicenter Study of Refractory and/or Relapsing Takayasu Arteritis START: Study of Refractory and/or Relapsing TAkayasu aRTeritis Recruiting NCT03543527
39 The PET Imaging of Giant Cell and Takayasu Arteritis Study Recruiting NCT04071691
40 China Takayasu Arteritis Registry (CTA Registry) Recruiting NCT02964364
41 Determining the Association Between Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity Recruiting NCT03941184
42 Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis Recruiting NCT02257866
43 VCRC Tissue Biorepository Collection Protocol Recruiting NCT02967068
44 The Vasculitis Pregnancy Registry (V-PREG) Recruiting NCT02593565
45 Chronic Childhood Vasculitis: Characterizing the Individual Rare Diseases to Improve Patient Outcomes Recruiting NCT02006134
46 Aortitis and Retroperitoneal Fibrosis: Evaluation of Diagnostic Criteria Recruiting NCT03133949
47 Clinical Characteristics of Allergy, Autoimmune and Rheumatic Diseases: A Ten Year Retrospective Study Recruiting NCT01611636
48 VCRC Longitudinal Protocol for Takayasu's Arteritis Active, not recruiting NCT00315471
49 VCRC Longitudinal Protocol for Aortitis Active, not recruiting NCT03022331
50 The Effects and Safety of Drug-coated Balloon in the Treatment of Hypertension Caused by Takayasu Arteritis Associated Renal Artery Stenosis: a Single Centre, Random, Double Blind Trial Not yet recruiting NCT04137614

Search NIH Clinical Center for Takayasu Arteritis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Alprostadil

Cochrane evidence based reviews: takayasu arteritis

Genetic Tests for Takayasu Arteritis

Anatomical Context for Takayasu Arteritis

MalaCards organs/tissues related to Takayasu Arteritis:

40
Heart, Bone, Kidney, T Cells, Lung, Thyroid, Skin

Publications for Takayasu Arteritis

Articles related to Takayasu Arteritis:

(show top 50) (show all 2005)
# Title Authors PMID Year
1
Two susceptibility loci to Takayasu arteritis reveal a synergistic role of the IL12B and HLA-B regions in a Japanese population. 61 56
23830516 2013
2
Identification of multiple genetic susceptibility loci in Takayasu arteritis. 61 56
23830517 2013
3
Matrix metalloproteinases as novel disease markers in Takayasu arteritis. 61 56
12952836 2003
4
DNA typing of HLA-B gene in Takayasu's arteritis. 61 56
7903491 1993
5
Takayasu's disease in twin sisters. 56
6145807 1984
6
HLA-DR MT and MB antigens in Takayasu disease. 56
6134351 1983
7
Association between Takayasu's arteritis and a B-cell alloantigen in North Americans. 56
6977091 1982
8
HL-A antigens in Takayasu's disease. 56
36742 1979
9
Association between Takayasu disease and HLA-DHO. 56
91228 1979
10
HLA-Bw52 in Takayasu disease. 56
31708 1978
11
Takayasu's disease in twin sisters. Possible genetic factors. 56
25719 1978
12
TAKAYASU'S ARTERITIS. REPORT OF FIVE CASES WITH IMMUNOLOGIC STUDIES. 56
14176969 1964
13
Pulmonary Artery Involvement in Patients with Takayasu Arteritis. 61
31092716 2020
14
Thoracoabdominal Aortic Aneurysm in a Patient With Takayasu Arteritis. 61
31254506 2020
15
Dissecting Thoracic Aneurysm in Takayasu Arteritis With Concomitant Tuberculosis. 61
31255612 2020
16
Efficacy and safety of leflunomide treatment in Takayasu arteritis: Case series from the East China cohort. 61
31350057 2020
17
Targeting Mechanistic Target of Rapamycin Complex 1 Restricts Proinflammatory T Cell Differentiation and Ameliorates Takayasu Arteritis. 61
31430047 2020
18
Insufficient Use of Corticosteroids without Immunosuppressants Results in Higher Relapse Rates in Takayasu Arteritis. 61
31092708 2020
19
Disease progression of Takayasu arteritis in two patients treated with tocilizumab. 61
30530823 2020
20
CD4+ T cells as key players in the immunopathology of Takayasu arteritis: comment on the article by Zhang et al. 61
31876121 2020
21
Elevated antistreptolysin O titer is closely related to cardiac mitral insufficiency in untreated patients with Takayasu arteritis. 61
32013899 2020
22
Brachial-Ankle Pulse Wave Velocity is Increased and Associated with Disease Activity in Patients with Takayasu Arteritis. 61
31270281 2020
23
Prognosis of large vessel involvement in large vessel vasculitis. 61
32035747 2020
24
Surgical treatment in patients with aortic regurgitation due to Takayasu arteritis (Commentary). 61
31958423 2020
25
Enlarging aneurysm of the ascending aorta in a pregnant woman with Takayasu arteritis. 61
31724561 2020
26
Effectiveness of Tocilizumab in juvenile patients with refractory Takayasu arteritis: Two case reports. 61
31977898 2020
27
Novel ultrawide field fundus fluorescein angiographic findings in a patient of Takayasu arteritis on immunosuppression. 61
31856538 2020
28
Refractory Takayasu arteritis responding to the oral Janus kinase inhibitor, tofacitinib. 61
32016168 2020
29
Takayasu arteritis in a rural hospital in Indonesia. 61
31919057 2020
30
Vascular ultrasound for monitoring of inflammatory activity in Takayasu arteritis. 61
31605660 2020
31
Does microbiome contribute to HLA-B52-positive Takayasu arteritis? 61
30793628 2020
32
Pregnency with Takayasu Arteritis. 61
31979709 2020
33
Isolated peripheral pulmonary stenosis in Takayasu arteritis. 61
31746147 2020
34
Percutaneous Renal Artery Stenting With Optical Coherence Tomography Imaging in a Young Boy With Recanalized-Thrombus Associated Renal Artery Stenosis. 61
31893504 2020
35
Clinical Characteristics and Long-Term Outcomes of Midaortic Syndrome. 61
31923594 2020
36
Giant coronary aneurysms, from diagnosis to treatment: A literature review. 61
31866173 2020
37
2018 Update of the EULAR recommendations for the management of large vessel vasculitis. 61
31270110 2020
38
Effect of Treatment on Imaging, Clinical, and Serologic Assessments of Disease Activity in Large-vessel Vasculitis. 61
30877209 2020
39
Association between plasma fibroblast growth factor 23 and left ventricular mass index in patients with Takayasu arteritis. 61
31897962 2020
40
Efficacy and safety of tocilizumab in treatment of Takayasu arteritis: A systematic review of randomized controlled trials. 61
32000551 2020
41
Restenosis of Bilateral Aorta-Renal Saphenous Vein Grafts after the Surgical Repair of Takayasu Arteritis-induced Bilateral Renal Arteries Stenosis: Case Report. 61
31449935 2020
42
Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study. 61
31951279 2020
43
Takayasu arteritis: Anaesthetic implications in caesarean section. 61
31054521 2019
44
Pregnancy and Takayasu arteritis: case-based review. 61
31858208 2019
45
Basilar Tip Aneurysm in Takayasu Arteritis. 61
31938555 2019
46
Takayasu Arteritis Type V. 61
31865032 2019
47
Isoniazid-induced Takayasu arteritis remission. 61
31846995 2019
48
[Takayasu arteritis of atypical presentation. Tocilizumab as an alternative therapeutic option]. 61
30777717 2019
49
An Observational Study of Sex Differences in Takayasu Arteritis in China: Implications for Worldwide Regional Differences. 61
31863951 2019
50
Endovascular Treatment of Iliac Artery Stenosis Caused by Takayasu Arteritis: A 10-Year Experience. 61
31496339 2019

Variations for Takayasu Arteritis

Expression for Takayasu Arteritis

Search GEO for disease gene expression data for Takayasu Arteritis.

Pathways for Takayasu Arteritis

Pathways related to Takayasu Arteritis according to GeneCards Suite gene sharing:

(show all 49)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.98 VCAM1 TNF PTX3 MMP9 MMP3 MICA
2
Show member pathways
13.49 VCAM1 MICA ICAM1 HLA-DRB1 HLA-DPB1 HLA-B
3
Show member pathways
13.38 VCAM1 TNF MMP9 MMP3 IL6 IL12B
4
Show member pathways
12.96 TNF MICA IL6 ICAM1 HLA-B HLA-A
5
Show member pathways
12.91 TNF IL6 IL12B ICAM1 HLA-DRB1 HLA-DPB1
6 12.86 TNF IL6 IL12B HLA-DRB1 HLA-DPB1 HLA-B
7
Show member pathways
12.7 TNF MICA IL6 IL12B ICAM1 HLA-DRB1
8
Show member pathways
12.65 TNF IL12B HLA-DRB1 HLA-DPB1 CD40LG
9
Show member pathways
12.62 TNF IL6 IL12B HLA-DRB1 HLA-DPB1
10
Show member pathways
12.61 VCAM1 ICAM1 HLA-DRB1 HLA-DPB1 HLA-B HLA-A
11
Show member pathways
12.59 TNF MICA ICAM1 HLA-B HLA-A FCGR3A
12 12.44 TNF IL6 ICAM1 HLA-DRB1 HLA-DPB1 HLA-B
13
Show member pathways
12.34 TNF IL12B HLA-DRB1 HLA-DPB1 FCGR3A FCGR2A
14
Show member pathways
12.33 TNF MMP9 MMP3 IL6
15
Show member pathways
12.33 TNF IL6 ICAM1 CRP
16 12.31 TNF IL6 IL12B HLA-DRB1 HLA-DPB1 FCGR3A
17
Show member pathways
12.29 TNF IL6 IL12B HLA-B HLA-A
18 12.25 HLA-DRB1 HLA-DPB1 HLA-B HLA-A FCGR3A FCGR2A
19 12.2 VCAM1 TNF THBD SELE MMP9 ICAM1
20
Show member pathways
12.14 TNF MMP9 MMP3 IL6 FCGR3A FCGR2A
21 12.11 VCAM1 MICA ICAM1 HLA-B HLA-A FCGR3A
22 12.09 TNF MMP9 IL6 ICAM1 FCGR2A
23 12.06 VCAM1 MMP9 MMP3 ICAM1
24 12.02 VCAM1 TNF THBD SELE IL6 ICAM1
25 12.01 VCAM1 TNF MMP9 MMP3 IL6 IL12B
26 11.99 ICAM1 HLA-DRB1 HLA-DPB1 FCGR3A FCGR2A
27 11.98 TNF MMP3 IL6 ICAM1 HLA-DRB1 HLA-DPB1
28 11.97 VCAM1 TNF ICAM1 CD40LG
29 11.96 TNF IL6 HLA-DRB1 HLA-DPB1
30 11.96 VCAM1 TNF SELE MMP9 MMP3 IL6
31 11.81 TNF MMP9 MMP3 IL6 FCGR3A FCGR2A
32 11.79 SELE IL6 ICAM1
33 11.78 TNF PTX3 MMP9 IL6 IL12B
34 11.76 TNF IL6 IL12B
35 11.75 TNF THBD IL6
36 11.73 VCAM1 SELE ICAM1 HLA-DRB1 HLA-DPB1 HLA-B
37 11.62 TNF IL6 IL12B
38 11.62 TNF IL6 IL12B ICAM1
39 11.6 TNF MMP9 IL6 ICAM1
40 11.52 VCAM1 SELE ICAM1
41 11.5 VCAM1 TNF SELE IL6 ICAM1 CD40LG
42 11.44 SELE MMP9 MMP3
43 11.38 THBD MMP9 IL6
44 11.37 TNF IL6 IL12B HLA-DRB1
45 11.35 TNF IL6 IL12B
46 11.2 VCAM1 TNF SELE IL6 IL12B ICAM1
47 11.11 TNF IL6 CRP
48 11.03 VCAM1 TNF ICAM1
49
Show member pathways
11.02 VCAM1 TNF SELE MMP9 MMP3 IL6

GO Terms for Takayasu Arteritis

Cellular components related to Takayasu Arteritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.22 VCAM1 TNF THBD SELE MICA ICAM1
2 integral component of plasma membrane GO:0005887 10.02 VCAM1 TNF THBD SELE MICA ICAM1
3 external side of plasma membrane GO:0009897 9.81 VCAM1 TNF MICA IL12B ICAM1 HLA-DRB1
4 extracellular space GO:0005615 9.8 VCAM1 TNF THBD SELE PTX3 MMP9
5 ER to Golgi transport vesicle membrane GO:0012507 9.62 HLA-DRB1 HLA-DPB1 HLA-B HLA-A
6 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.56 HLA-DRB1 HLA-DPB1 HLA-B HLA-A
7 MHC class I protein complex GO:0042612 9.43 HLA-B HLA-A
8 cell surface GO:0009986 9.36 VCAM1 TNF THBD MICA IL12B ICAM1

Biological processes related to Takayasu Arteritis according to GeneCards Suite gene sharing:

(show all 30)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.97 TNF SELE PTX3 IL6 CRP CD40LG
2 leukocyte migration GO:0050900 9.91 TNF THBD SELE ICAM1
3 cellular response to lipopolysaccharide GO:0071222 9.91 TNF IL6 IL12B ICAM1
4 response to lipopolysaccharide GO:0032496 9.89 VCAM1 THBD SELE ICAM1
5 extracellular matrix organization GO:0030198 9.88 VCAM1 TNF PTX3 MMP9 MMP3 ICAM1
6 cytokine-mediated signaling pathway GO:0019221 9.87 VCAM1 TNF MMP9 MMP3 IL6 IL12B
7 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.84 TNF IL6 ICAM1 CD40LG
8 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.8 TNF IL6 IL12B
9 heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules GO:0007157 9.76 VCAM1 SELE ICAM1
10 positive regulation of nitric oxide biosynthetic process GO:0045429 9.73 TNF PTX3 ICAM1
11 antigen processing and presentation GO:0019882 9.73 HLA-DRB1 HLA-DPB1 HLA-B HLA-A
12 positive regulation of interferon-gamma production GO:0032729 9.72 TNF IL12B HLA-DPB1
13 positive regulation of T cell mediated cytotoxicity GO:0001916 9.7 MICA IL12B HLA-B
14 regulation of immune response GO:0050776 9.7 VCAM1 MICA ICAM1 HLA-B HLA-A FCGR3A
15 leukocyte tethering or rolling GO:0050901 9.69 VCAM1 TNF SELE
16 leukocyte cell-cell adhesion GO:0007159 9.67 VCAM1 SELE ICAM1 CD40LG
17 T cell mediated cytotoxicity GO:0001913 9.65 MICA HLA-A
18 regulation of neuroinflammatory response GO:0150077 9.65 MMP9 MMP3 IL6
19 positive regulation of T cell proliferation GO:0042102 9.65 VCAM1 IL6 IL12B HLA-DPB1 CD40LG
20 T-helper 1 type immune response GO:0042088 9.64 IL12B HLA-DRB1
21 antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent GO:0002486 9.64 MICA HLA-B
22 antigen processing and presentation of endogenous peptide antigen via MHC class Ib GO:0002476 9.63 MICA HLA-B
23 negative regulation of lipid storage GO:0010888 9.63 TNF IL6 CRP
24 opsonization GO:0008228 9.62 PTX3 CRP
25 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.62 HLA-B HLA-A
26 immune response GO:0006955 9.61 TNF MICA IL6 HLA-DRB1 HLA-DPB1 HLA-B
27 protection from natural killer cell mediated cytotoxicity GO:0042270 9.6 HLA-B HLA-A
28 regulation of immunoglobulin secretion GO:0051023 9.58 TNF CD40LG
29 membrane to membrane docking GO:0022614 9.57 VCAM1 ICAM1
30 interferon-gamma-mediated signaling pathway GO:0060333 9.1 VCAM1 ICAM1 HLA-DRB1 HLA-DPB1 HLA-B HLA-A

Molecular functions related to Takayasu Arteritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.56 TNF IL6 IL12B CD40LG
2 IgG binding GO:0019864 9.32 FCGR3A FCGR2A
3 beta-2-microglobulin binding GO:0030881 9.16 MICA HLA-A
4 complement component C1q binding GO:0001849 8.96 PTX3 CRP
5 peptide antigen binding GO:0042605 8.92 HLA-DRB1 HLA-DPB1 HLA-B HLA-A

Sources for Takayasu Arteritis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....